S.F. SUBKHANKULOVA¹, R.I. GABIDULLINА², A.O. POZDNYAK¹

 ¹Kazan State Medical Academy — Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan

²Kazan State Medical University, Kazan

 Contact details:

Subkhankulova S.F. — PhD (Medicine), Associate Professor of the Department of Therapy, Geriatrics and Family Medicine

Address: 36 Butlerov St., 420012 Kazan, Russian Federation, tel.: +7-917-259-86-14, e-mail: sfs-kazan@yandex.ru

With the increase in the number of women of mature and elderly age, the question arises of maintaining health and quality of life during menopause. Although menopause is a physiological phenomenon, most women develop menopausal syndrome, which significantly worsens their overall well-being. The most effective method of treating menopausal syndrome is MHT — menopausal hormone therapy, which is most advisable to start during the menopausal transition and early menopause. However, the use of MHT can provoke thromboembolic and oncological complications. Therefore, a personalized approach to each patient is the most effective, taking into account the category of MHT acceptability by age and the presence of extragenital diseases.

Key words: menopause, metabolic syndrome, cardiovascular diseases, menopausal hormone therapy.

REFERENCES

1. Ulumbekova G.E., Khudova I.Yu. Assessment of the demographic, social and economic effect of menopausal hormone therapy. ORGZDRAV: news, opinions, training. Vestnik VShOUZ, 2020, no. 6 (4 (22)), pp. 23–53 (in Russ.). DOI: 10.24411/2411-8621-2020-14002
2. Ministerstvo zdravookhraneniya Rossiyskoy Federatsii. Klinicheskie rekomendatsii. Menopauza i klimaktericheskoe sostoyanie u zhenshchiny [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and climacteric state in women], 2021.
3. Park S.U., Walsh L., Berkowitz K.M. Mechanisms of ovarian aging. Reproduction, 2021, vol. 162 (2), pp. R19–R33.
4. Turner R.J., K1erber I.J. A theory of eu-estrogenemia: a unifying concept. Menopause, 2017, vol. 24 (9), 10861097. DOI: https://doi.org/10.1097/GME.0000000000000895
5. Santoro N., Roeca C., Peters B.A., Neal-Perry G. The menopause transition: signs, symptoms, and management options. J. Clin. Endocrinol. Metab, 2021, vol. 106 (1), pp. 1–15.
6. Cappola A.R., Auchus R.J., El-Hajj Fuleihan G. et al. Hormones and Aging: An Endocrine Society Scientific Statement. J. Clin. Endocrinol. Metabol, 2023, vol. 108, pp. 1835–1874. DOI: 10.1210/clinem/dgad225
7. Manson J.E., Bassuk S.S., Kaunitz A.M., Pinkerton J.V. The women’s health initiative trials of menopausal hormone therapy: lessons learned. Menopause, 2020, vol. 27 (8), pp. 918–928.
8. Johansson T., Fowler P., Ek W.E. et al. Oral contraceptives, hormone replacement therapy, and stroke risk. Stroke, 2022, vol. 53 (10), pp. 3107–3115. DOI: 10.1161/STROKEAHA.121.038659
9. El Khoudary S.R., Aggarwal B., Beckie T.M., Hodis H.N., Johnson A.E., Langer R.D. et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation, 2020, vol. 142 (25), pp. e506–532. DOI: 10.1161/CIR.0000000000000912
10. Cho L., Kaunitz A.M., Faubion S.S., Hayes S.N., Lau E.S., Pristera N. et al. Rethinking menopausal hormone therapy: for whom, what, when, and how long? Circulation, 2023, vol. 147 (7), pp. 597–610. DOI: 10.1161/CIRCULATIONAHA.122.061559
11. Lambrinoudaki I., Armeni E., Goulis D., Bretz S., Ceausu I., Durmusoglu F. et al. Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas, 2022, vol. 163, pp. 1–14. DOI: 10.1016/j.maturitas.2022.04.008
12. Park Y.J., Kim J.M. Klotho and postmenopausal hormone replacement therapy in women with chronic kidney disease. J. Menopausal Med, 2018, vol. 24 (2), pp. 75–80. DOI: 10.6118/jmm.2018.24.2.75. 7
13. Ibrahim A., Hugerth L.W., Hases L. et al. Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity. Int. J. Cancer, 2019, vol. 144 (12), pp. 3086–3098.
14. Li K., Chen L., Huang Y., Luan X. Meta-analysis for the effect of hormone replacement therapy on survival rate in female with lung cancer. Zhong Nan Da Xue Bao Yi Xue Ban, 2020, vol. 45 (4), pp. 372–377.
15. Mendoza N., Ramírez I., De La Viuda E., Coronado P., Baquedano L., Llaneza P. et al. Eligibility criteria for menopausal hormone therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT eligibility criteria group. Maturitas, 2022, vol. 166, pp. 65–85. DOI: 10.1016/j.maturitas.2022.08.008
16. The 2022 hormone therapy position statement of The North America n Menopause Society. Menopause, 2022, vol. 29 (7), pp. 767–794. DOI: 10.1097/GME.0000000000002028
17. Hirschberg A.L., Bitzer J., Cano A., Ceausu I., Chedraui P., Durmusoglu F. et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas, 2021, vol. 148, pp. 55–61. DOI: 10.1016/j.maturitas.2021.04.005
18. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause, 2020, vol. 27 (9), pp. 976–992. DOI: 10.1097/GME.0000000000001609
19. Yureneva S.V. Menopausal hormone therapy — an individualized approach from the standpoint of efficacy and safety: a review of international recommendations. Akusherstvo i ginekologiya, 2024, no. 9, pp. 36–46 (in Russ.). DOI: 10.18565/aig.2024.224
20. Kapoor E., Kling J.M., Lobo A.S., Faubion S.S. Menopausal hormone therapy in women with medical conditions. Best Pract. Res. Clin. Endocrinol. Metabol, 2021, vol. 35 (6), 101578. DOI: 10.1016/j.beem.2021.101578
21. Shlyakhto E.V., Sukhikh G.T., Serov V.N., Dedov I.I., Arutyunov G.P., Suchkov I. A. et al. Russian eligibility criteria for prescribing menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Consensus document of the Russian Society of Cardiology, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia. Kardiologiya, 2023, no. 63 (10), pp. 9–28 (in Russ.).
22. Ofori E.K., Conde Alonso S., Correas-Gomez L et al. Thigh and abdominal adipose tissue depot associations with testosterone levels in postmenopausal females. Clin. Endocrinol. (Oxf), 2019, vol. 90 (3), pp. 433–439.
23. Markova T.N. Obesity and associated diseases. Modern possibilities of prevention and treatment in real clinical practice. Farmateka, 2019, no. 4, pp. 122–127 (in Russ.).
24. LaVasseur C., Neukam S., Kartika T., Samuelson Bannow B., Shatzel J., DeLoughery T.G. Hormonal therapies and venous thrombosis: Considerations for prevention and management. Res. Pract. Thromb. Haemostasis, 2022, vol. 6 (6), e12763. DOI: 10.1002/rth2.12763
25. Sobel T.H., Shen W. Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scopin g review. Menopause, 2022, vol. 29 (4), pp. 483–490. DOI: 10.1097/GME.0000000000001938
26. Kim J.E., Choi J., Park J., Lee J.K., Shin A., Park S.M. et al. Associations of postmenopausal hormone therapy with metabolic syndrome among diabetic and non-diabetic women. Maturitas, 2019, vol. 121, pp. 76–82. DOI: 10.1016/j.maturitas.2018.12.012
27. Orlova Ya.A., Plisyuk A.G., Dolgushin G.O., Kirillova K.I., Mikheev R.K., Andreeva E.N. The relationship between long-term menopausal hormone therapy and indicators of vascular and replicative aging in women. Profilakticheskaya meditsina, 2023, no. 26 (7), pp. 96–102 (in Russ.). DOI: 10.17116/profmed20232607196
28. Klinicheskie rekomendatsii “Algoritmy spetsializirovannoy meditsinskoy pomoshchi bol’nym sakharnym diabetom”, pod red. I.I. Dedova, M.V. Shestakovoy, A.Yu. Mayorova. Vyp. 9 [Clinical guidelines «Algorithms for specialized medical care for patients with diabetes mellitus», edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. Issue. 9]. Moscow, 2019. DOI: 10.14341/DM221S1.
29.  Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis based on diabetes mellitus registry data as of 01.01.2021. Sakharnyy diabet, 2021, no. 24 (3), pp. 204–221 (in Russ.). DOI: 10.14341/DM12759
30. Slopien R., Wender-Ozegowska E., Rogowicz-Frontczak A., Meczekalski B., Zozulinska-Ziolkiewicz D., Jaremek J.D. et al. Menopause and diabetes: EMAS clinical guide. Maturitas, 2018, vol. 117, pp. 6–10. DOI: 10.1016/j.maturitas.2018.08.009
31. Nappi R.E., Chedraui P., Lambrinoudaki I., Simoncini T. Menopause 1. Menopause: a cardiometabolic transition. Lancet Diab. Endocrinol, 2022, vol. 10, pp. 442–456.
32. Roeters van Lennep J.E., Tokgözoğlu L.S., Badimon L. et al. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society. Eur. Heart J, 2023, ehad472. DOI: 10.1093/eurheartj/ehad472
33. Anagnostis P., Bitzer J., Cano A., Ceausu I., Chedraui P., Durmusoglu F. et al. Menopause symptom management in women with dyslipidemias: an EMAS clinical guide. Maturitas, 2020, vol. 135, pp. 82–88. DOI: 10.1016/j.maturitas.2020.03.007
34. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, VII revision. Ateroskleroz i dislipidemii, 2020, no. 1 (38), pp. 7–42 (in Russ.). DOI: 10.34687/2219-8202.JAD.2020.01.0002
35. Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., Ansheles A.A. et al. Lipid metabolism disorders. Clinical guidelines 2023. Rossiyskiy kardiologicheskiy zhurnal, 2023, no. 28 (5), pp. 250–297 (in Russ.). DOI: 10.15829/1560-4071-2023-5471
36. Maas A., Rosano G., Cifkova R., Chieffo A., van Dijken D., Hamoda H. et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur. Heart J, 2021, vol. 42 (10), pp. 967–984. DOI: 10.1093/eurheartj/ehaa1044
37. Arterial hypertension in adults. Clinical guidelines 2020. Rossiyskiy kardiologicheskiy zhurnal, 2020, no. 25 (3), p. 3786 (in Russ.). DOI: 10.15829/1560-4071-2020-3-3786
38. Samargandy S., Matthews K.A., Brooks M.M. et al. Trajectories of blood pressure in midlife women: does menopause matter? Circ. Res, 2022, vol. 130 (3), pp. 312–322.
39. Vogel B., Acevedo M., Appelman Y., Bairey Merz C.N., Chieffo A., Figtree G.A. et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet, 2021, vol. 397 (10292), pp. 2385–2438. DOI: 10.1016/S0140-6736(21)00684-X
40. Shufelt C.L., Manson J.E. Menopausal hormone therapy and cardiovascular disease: the role of formulation, dose, and route of delivery. J. Clin. Endocrinol. Metab, 2021, vol. 106 (5), pp. 1245–1254.
41. Kim C., Catov J., Schreiner P.J. et al. Women’s reproductive milestones and cardiovascular disease risk: a review of reports and opportunities from the CARDIA study. J. Am. Heart Assoc, 2023, vol. 12 (5), e028132. DOI: 10.1161/JAHA.122.028132
42. Dubrovina S.O. Rational approach to hormonal therapy in women over 40 years old. Akusherstvo i ginekologiya, 2019, no. 7, pp. 112–116 (in Russ.). DOI: 10.18565/aig.2019.7.112-116
43. Radzinskiy V.E. Ocherki endokrinnoy ginekologii [Essays on endocrine gynecology]. Moscow: Mediabyuro Status Prezens, 2020. 576 p.
44. Madyanov I.V., Madyanova T.S. Menopauzal’naya gormonal’naya terapiya. V pomoshch’ terapevtu i vrachu obshchey praktiki [Menopausal hormone therapy. To help the therapist and general practitioner]. Moscow: GEOTAR-Media, 2018. 160 p.
45. Subkhankulova A.F., Subkhankulova S.F. Women’s health at an elegant age: the possibilities of menopausal hormone therapy. Farmateka, 2021, no. 6, pp. 8–13 (in Russ.).